ARYx to Present at the Jefferies 3rd Annual Healthcare Conference.

FREMONT, Calif. -- ARYx Therapeutics, Inc. (NASDAQ:ARYX) today announced that it will present at the Jefferies & Company 3rd Annual Healthcare Conference on Wednesday, June 17, 2009 at 2:45 p.m. Eastern Time. A live webcast of the presentation may be accessed at the ARYx website http://www.aryx.com. The presentation will be archived for 30 days.

About ARYx Therapeutics, Inc.

ARYx Therapeutics is a biopharmaceutical company focused on developing a portfolio of internally discovered products designed to eliminate known safety issues associated with well-established, commercially successful drugs. ARYx uses its RetroMetabolic Drug Design technology to design structurally unique molecules that retain the efficacy of these original drugs but are metabolized through a potentially safer pathway to avoid specific adverse side effects associated with these compounds. ARYx currently has four products in clinical development: an oral anticoagulant agent for patients at risk for the formation of dangerous blood clots, tecarfarin (previously ATI-5923); an oral anti-arrhythmic agent for the treatment of atrial fibrillation, budiodarone (previously ATI-2042); a prokinetic agent for the treatment of various gastrointestinal disorders, ATI-7505; and, an agent for the treatment of schizophrenia and other psychiatric disorders, ATI-9242. Please visit our web site at www.aryx.com for additional information.